Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Salerno

Internal Medicine East Orange, NJ Medical Doctor

NPI 1962476903 CMS profile 315430

613 Park Ave, East Orange, NJ 07017

Open in the dashboard

General payments

$90,850

237 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Salerno of East Orange, NJ is reported in the CMS Open Payments database as having received $90,850 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,402 17
2024 General $16,947 14
2023 General $9,818 15
2022 General $9,994 29
2021 General $10,360 60
2020 General $8,774 33
2019 General $7,556 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Salerno
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Alexander Salerno were reported at $27,402. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Alexander Salerno Internal Medicine median Middle half National median
2019 $7,556 $159 $48–$570 $163
2020 $8,774 $119 $33–$402 $114
2021 $10,360 $135 $37–$521 $132
2022 $9,994 $141 $42–$496 $149
2023 $9,818 $149 $45–$519 $160
2024 $16,947 $154 $47–$537 $164
2025 $27,402 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $83,201 23 payments
  2. Roche Diagnostics Corporation $2,750 1 payment
  3. Novartis Pharmaceuticals Corporation $2,015 16 payments
  4. AbbVie, Inc. $627 49 payments
  5. Novo Nordisk Inc $522 34 payments
  6. GlaxoSmithKline, LLC. $441 33 payments
  7. Lilly USA, LLC $227 17 payments
  8. Pfizer Inc. $148 10 payments
  9. Madrigal Pharmaceuticals $124 2 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $121 8 payments
  11. Other $674 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $63,080 14 payments
  2. Education $20,023 8 payments
  3. Consulting Fee $4,502 2 payments
  4. Food and Beverage $3,245 213 payments
Products named General payments · program years 2019–2025
  1. VenaCure 1470 Pro Et $45,639 11 payments
  2. VenaCure 1470 Pro Id $27,093 6 payments
  3. EVLT $10,400 4 payments
  4. POC cobas Liat Analyzer, Assays, Controls and Accessories $2,750 1 payment
  5. Ozempic $368 30 payments
  6. VRAYLAR $308 20 payments
  7. TRELEGY ELLIPTA $257 18 payments
  8. UBRELVY $186 19 payments
  9. JARDIANCE $174 13 payments
  10. ENTRESTO $142 11 payments
  11. Other $1,948 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

8,583

Median for Internal Medicine: 777

Drug cost

$2,480,657

Median for Internal Medicine: $73,373

Branded share of claims

39.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qutenza Capsaicin/Skin Cleanser Brand 208 $732,611
Jardiance Empagliflozin Brand 206 $182,920
Eliquis Apixaban Brand 216 $156,228
Mounjaro Tirzepatide Brand 123 $140,157
Repatha Sureclick Evolocumab Brand 181 $127,284
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 166 $114,424
Enbrel Etanercept Brand 13 $103,741
Trulicity Dulaglutide Brand 85 $96,531
Ozempic Semaglutide Brand 84 $86,926
Kerendia Finerenone Brand 101 $85,683

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$770,176

Of which drugs: $30,959

Medicare patients

812

Average age 70

Services billed

12,175

506 women, 306 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Chronic kidney disease 51%
Arthritis 35%
Depression 31%
Ischemic heart disease 25%
COPD 25%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 57 57 $16,400
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 32 32 $4,761
Vaccine for Hepatitis B adult dosage (2 dose schedule) injection into muscle 90739 Office 14 20 $3,283
Vaccine for influenza for injection into muscle 90662 Office 34 35 $2,725
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 49 99 $89
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 50 $27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $49
$49 — —
LINZESS
  • AbbVie, Inc. $22
$22 41 —
CREON
  • AbbVie, Inc. $22
$22 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $17
$17 166 —
RYBELSUS
  • Novo Nordisk Inc $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record